SIREN : 811545649
SAS BIOBOTIGA is a French company founded 11 years ago, specialized in the sector Autres commerces de détail spécialisés divers. Based in LE BOULOU (66160), this company of category PME shows in 2025 a revenue of 1.5 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 548 128 € | 1 505 755 € | 1 598 922 € | 1 663 528 € | 1 930 736 € | N/C | N/C | N/C | 1 478 536 € | 1 045 253 € |
| Net income | 321 € | -38 833 € | -47 823 € | -25 604 € | 69 365 € | 68 199 € | 17 950 € | 20 233 € | 56 135 € | 1 788 € |
| EBITDA | 4 765 € | -41 968 € | -3 228 € | 10 730 € | 119 492 € | N/C | N/C | N/C | 118 505 € | 49 395 € |
| Net margin | 0.0% | -2.6% | -3.0% | -1.5% | 3.6% | N/C | N/C | N/C | 3.8% | 0.2% |
In 2025, SAS BIOBOTIGA achieves revenue of 1.5 M€. Revenue is growing positively over 10 years (CAGR: +4.5%). Vs 2024: +3%. After deducting consumption (1.1 M€), gross margin stands at 455 k€, i.e. a rate of 29%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 5 k€, representing 0.3% of revenue. Positive scissor effect: EBITDA margin improves by +3.1 pts, sign of improved operational efficiency. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 321 €, i.e. 0.0% of revenue. This profit can be retained or distributed to shareholders.
1 548 128 €
454 600 €
4 765 €
2 452 €
321 €
0.3%
The debt ratio (= Financial debt / Equity x 100) stands at 138%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 27%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 68.3 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 0.2% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
137.882%
26.664%
0.151%
68.252
5.6%
In 2025, the debt ratio of SAS BIOBOTIGA (137.88) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2025, the financial autonomy of SAS BIOBOTIGA (26.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2025, the repayment capacity of SAS BIOBOTIGA (68.25) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 163.10. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 17.6x. Operating income very largely covers interest expenses: high safety margin.
163.104
17.587
In 2025, the liquidity ratio of SAS BIOBOTIGA (163.10) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2025, the interest coverage of SAS BIOBOTIGA (17.6x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 17 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 34 days. Favorable situation: supplier credit is longer than customer credit by 17 days. Inventory turnover is 32 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 50 days of revenue, i.e. 216 k€ to permanently finance. Over 2016-2025, WCR increased by +85%, requiring additional financing.
215 701 €
17 j
34 j
32 j
50 j
Based on 83 transactions of similar company sales
in 2025,
the value of SAS BIOBOTIGA is estimated at
127 117 €
(range 77 230€ - 248 622€).
With an EBITDA of 4 765€, the sector multiple of 2.2x is applied.
The price/revenue ratio is 0.26x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 83 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare SAS BIOBOTIGA with other companies in the same sector:
Voir toutes les statistiques du secteur Autres commerces de détail spécialisés divers
The revenue of SAS BIOBOTIGA in 2025 is 1.5 M€.
Yes, SAS BIOBOTIGA generated a net profit of 321€ in 2025.
The headquarters of SAS BIOBOTIGA is located in LE BOULOU (66160), in the department Pyrenees-Orientales.
The tax return of SAS BIOBOTIGA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
SAS BIOBOTIGA operates in the sector Autres commerces de détail spécialisés divers (NAF code 47.78C). See the 'Sector positioning' section above to compare the company with its competitors.